# Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

> **NCT06041529** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Yuhan Corporation** · enrollment: 198 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
- **DRUG:** Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg

## Key facts

- **NCT ID:** NCT06041529
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041529, "Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06041529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*